CAR-T Cell Therapy
CAR-T cell therapy is a personalized immunotherapy that modifies a patient’s T cells to recognize and attack certain blood cancers, particularly when other treatments have not worked.
Quick answer
CAR-T cell therapy is a personalized immunotherapy that modifies a patient’s T cells to recognize and attack certain blood cancers, particularly when other treatments have not worked.
CAR-T Cell Therapy: A Personalized Approach When Blood Cancer Needs Another Option
Learning that a blood cancer has returned, has not responded as hoped to treatment, or may require a more specialized approach can be profoundly difficult. Many patients and families arrive at this point after months or years of chemotherapy, targeted therapy, antibody treatment, stem cell transplantation, or a combination of these options. It is natural to have questions about what comes next, whether another treatment can still be effective, and how to make decisions while balancing medical urgency with quality of life.
CAR-T cell therapy is an advanced form of immunotherapy designed for selected blood cancers. Rather than relying only on medicines that attack cancer cells directly, it uses a patient’s own immune cells, called T cells, and modifies them in a specialized laboratory so they can better identify and attack cancer cells. It is not appropriate for every person or every type of cancer, but for carefully selected patients with certain relapsed or refractory blood cancers, it may offer an important treatment pathway.
The process is intensive and requires detailed planning, expert monitoring, and close coordination between hematology, oncology, cellular therapy, intensive care, neurology, infectious diseases, transfusion medicine, and supportive-care teams. For international patients, the decision also involves practical concerns: how long treatment may take, whether family can travel with them, what happens if side effects develop, and how follow-up will be arranged after returning home. A structured CAR-T program helps address these medical and personal needs from the earliest evaluation through recovery.
What Is CAR-T Cell Therapy?
CAR-T cell therapy, short for chimeric antigen receptor T-cell therapy, is a personalized cellular immunotherapy. T cells are white blood cells that play a central role in the immune system. In their natural form, however, they may not recognize cancer cells clearly enough or may become less effective in the cancer environment.
During CAR-T treatment, T cells are collected from the patient’s blood and sent to a specialized manufacturing facility. There, they are genetically modified to produce a receptor known as a chimeric antigen receptor, or CAR. This receptor is designed to recognize a specific marker, or antigen, found on the surface of certain cancer cells. Once the modified cells are returned to the patient through an intravenous infusion, they can seek out cells carrying that target and activate an immune response against them.
CAR-T therapy is different from chemotherapy. Chemotherapy circulates throughout the body and interferes with rapidly dividing cells, including cancer cells but sometimes healthy cells as well. CAR-T therapy is a living-cell treatment: the infused cells may multiply in the body, continue to recognize their target, and remain active for a variable period. This is one reason treatment can be powerful, but it is also why close observation is essential.
Current CAR-T therapies are primarily used for certain cancers of the blood and lymphatic system, especially specific types of leukemia, lymphoma, and multiple myeloma. The exact eligibility criteria depend on the disease type, its previous treatments, the cancer’s molecular and clinical features, available therapy options, and the patient’s overall health.
Who May Need CAR-T Cell Therapy?
CAR-T cell therapy is generally considered for patients with a blood cancer that has relapsed, meaning it returned after treatment, or is refractory, meaning it did not respond adequately to previous therapy. It is usually not the first treatment offered at diagnosis, although the place of CAR-T therapy in care is evolving as clinical evidence develops.
A patient may be referred for CAR-T evaluation after imaging, blood tests, bone marrow studies, lymph node biopsy, or other assessments show that cancer remains active despite prior treatment. In some cases, the referral occurs after relapse following stem cell transplantation. In others, a patient may have received several treatment lines and need a therapy that works through a different biological mechanism.
Symptoms vary widely by diagnosis. Lymphoma may cause enlarged lymph nodes, fever, night sweats, unintentional weight loss, fatigue, abdominal discomfort, or shortness of breath. Leukemia can lead to tiredness, frequent infections, bruising or bleeding, bone pain, fever, or abnormal blood counts. Multiple myeloma may cause persistent bone pain, fractures, anemia, recurrent infections, kidney problems, or elevated abnormal proteins in the blood. Some patients have few symptoms but show evidence of active disease on laboratory testing, imaging, or bone marrow examination.
Diagnosis and treatment planning are based on more than symptoms alone. Hematologists review pathology reports, prior treatment records, bone marrow findings, flow cytometry, genetic and molecular testing where relevant, imaging results, organ function, infection screening, and performance status. A careful review is particularly important because CAR-T treatment involves a period of immune suppression and may carry risks that need to be anticipated before cells are collected.
Not every patient with relapsed blood cancer is an immediate candidate. Factors such as uncontrolled infection, significant organ dysfunction, rapidly progressing disease, neurological concerns, prior therapies, and the availability of an appropriate cellular product may affect timing or suitability. Sometimes disease-controlling treatment, often called bridging therapy, is used while the CAR-T cells are being manufactured. The goal is to keep the cancer under appropriate control without compromising the planned cellular treatment.
Conditions CAR-T Cell Therapy May Address
CAR-T cell therapy is used in selected hematologic malignancies, with approved and appropriate indications differing according to the specific cellular product, local regulations, prior treatments, and individual clinical circumstances. The treatment team will determine whether a patient’s cancer expresses a suitable target and whether CAR-T therapy is the right option at that stage of care.
- Diffuse large B-cell lymphoma and related aggressive B-cell lymphomas: CAR-T therapy may be considered when disease has returned or has not responded after previous systemic treatment.
- Follicular lymphoma and other selected indolent B-cell lymphomas: In some patients with relapsed disease, cellular therapy may be considered after prior treatment approaches have been used.
- Mantle cell lymphoma: CAR-T therapy may be an option for selected patients whose disease has relapsed or remained resistant to other therapies.
- Acute lymphoblastic leukemia: Certain children, adolescents, young adults, and adults with relapsed or refractory B-cell acute lymphoblastic leukemia may be assessed for CAR-T treatment.
- Multiple myeloma: For selected patients with relapsed or refractory disease after several previous therapies, CAR-T therapy directed at myeloma-associated targets may be considered.
CAR-T therapy is not a single, identical treatment for every cancer. The target on the cancer cell, the manufacturing process, the treatment sequence, and the expected adverse effects may differ by diagnosis and cellular product. For this reason, an individualized assessment by a specialist cellular therapy team is essential.
How CAR-T Cell Therapy Is Performed
CAR-T treatment unfolds over several stages. Although the cell infusion itself is usually brief, the complete treatment journey commonly extends over weeks and includes evaluation, cell collection, manufacturing, preparation, monitoring, and planned follow-up.
Initial Evaluation and Treatment Planning
The process begins with a comprehensive consultation. The hematology and cellular therapy team reviews the diagnosis, pathology, prior therapies, current disease status, imaging, laboratory results, medications, and medical history. Blood tests evaluate kidney, liver, heart, lung, and bone marrow function. Screening for infections is important because treatment may temporarily weaken immune defenses.
In complex cases, the treatment plan may be reviewed by a multidisciplinary hematology or cellular therapy board. These discussions can include hematologists, medical oncologists, transplant and cellular therapy physicians, pathologists, radiologists, infectious disease specialists, intensive care physicians, neurologists, pharmacists, and nursing teams. The purpose is to determine whether CAR-T therapy is appropriate, define the safest timing, and plan for potential complications before treatment starts.
Collection of T Cells
T cells are collected through a procedure called leukapheresis. During leukapheresis, blood is drawn through a vein or, when needed, through a central venous catheter. A cell-separation system collects white blood cells containing T cells and returns the remaining blood components to the patient. The procedure commonly takes several hours and is usually performed while the patient is awake.
Patients may feel tired afterward, and some experience temporary tingling around the mouth or in the hands due to changes in calcium levels during collection. The clinical team monitors blood counts and symptoms throughout the process. In many cases, patients can leave the hospital the same day, depending on their overall condition and treatment plan.
Cell Manufacturing and Bridging Treatment
The collected cells are transferred to a specialized manufacturing laboratory, where they are modified, expanded, tested, and prepared for return. Manufacturing requires rigorous quality controls to confirm identity, potency, sterility, and suitability for infusion. This phase takes time, and the timeline can vary.
Because some blood cancers can progress during manufacturing, the medical team may recommend bridging therapy. This can include chemotherapy, targeted treatment, antibody-based therapy, corticosteroids, radiation therapy, or another individualized approach. Bridging treatment is selected carefully. It should help control disease while preserving the patient’s ability to proceed with CAR-T therapy.
Conditioning Chemotherapy
Before CAR-T cell infusion, patients often receive a short course of lymphodepleting chemotherapy. This is usually given over several days. It does not aim to eliminate the cancer by itself; rather, it reduces certain immune cells and creates conditions that may help the infused CAR-T cells expand and function effectively.
During this stage, blood counts may decrease, fatigue may increase, and infection precautions become particularly important. The care team provides supportive medications as needed, including anti-nausea treatment, hydration, infection prevention measures, and blood-product support when appropriate.
CAR-T Cell Infusion
The CAR-T cells are administered through an intravenous infusion, generally in a controlled inpatient setting or through a closely supervised outpatient pathway when clinically appropriate. The infusion itself is often completed within a relatively short period. It is usually not painful, although patients are monitored closely for fever, chills, breathing changes, low blood pressure, allergic-type reactions, or other early symptoms.
The days following infusion are among the most important parts of treatment. CAR-T cells can become activated and release inflammatory signals as they engage cancer cells. This immune activity is part of how the treatment works, but it can also cause side effects that require prompt recognition and treatment.
Technology and Monitoring Used During Treatment
CAR-T therapy depends on advanced cellular processing, controlled cryopreservation and transport systems, laboratory quality assurance, and detailed patient monitoring. Modern diagnostic pathways help clinicians assess disease burden before treatment and measure response afterward using blood tests, bone marrow evaluation, molecular testing where indicated, and advanced imaging techniques.
During the monitoring period, patients may have frequent blood tests, continuous or repeated checks of vital signs, neurological assessments, infection screening, and organ-function monitoring. Digital clinical systems can help teams recognize trends in fever, blood pressure, oxygen levels, inflammatory markers, and blood counts. Intensive care capabilities are available for the small proportion of patients who develop serious complications requiring higher-level support.
Typical Duration and Immediate Recovery
The full CAR-T pathway is individualized. The initial evaluation and cell collection may occur within days or weeks, while cell manufacturing and any bridging treatment can extend the process. After infusion, patients generally remain near the treatment center for close observation. The exact hospital stay varies based on the diagnosis, treatment protocol, side effects, and local clinical requirements.
Recovery after CAR-T therapy is gradual. The immune system and blood counts can take time to recover, and patients may need regular follow-up for months. Many patients require a caregiver nearby during the initial post-treatment period because fatigue, infection risk, and delayed complications can occur.
Why Acting Early Matters
For patients with relapsed or refractory blood cancer, timing matters. CAR-T therapy requires planning, cell collection, manufacturing, and preparation before the infusion can take place. A referral for evaluation should therefore occur before disease progression becomes too rapid or a patient’s condition becomes too fragile for intensive treatment.
Delaying specialist assessment may reduce available options. Progressive cancer can cause worsening symptoms, declining blood counts, organ complications, infections, or a reduced ability to tolerate bridging treatment and lymphodepleting chemotherapy. In aggressive lymphoma or leukemia, disease can change quickly, making early communication with a cellular therapy center particularly important.
Early evaluation does not mean every patient will proceed directly to CAR-T therapy. It means the care team can assess eligibility, arrange necessary testing, discuss alternatives, and create a plan that reflects the current disease status. For some patients, the most appropriate next step may be another systemic therapy, a clinical trial where available, radiation, stem cell transplantation, supportive care, or a carefully sequenced combination of approaches.
Potential Benefits of CAR-T Cell Therapy
For appropriately selected patients, CAR-T therapy may provide benefits that differ from those of conventional treatment approaches.
| Benefit | What It Means for You |
|---|---|
| Personalized use of your own immune cells | Your T cells are collected and modified to recognize a defined marker on the cancer cells, creating a treatment designed around your immune system. |
| A different mechanism from standard chemotherapy | CAR-T therapy may be considered when previous treatments have not controlled the cancer sufficiently or when a new therapeutic strategy is needed. |
| Potential for deep disease response | Some patients with relapsed or refractory blood cancers achieve significant responses. The likelihood and durability of response depend on the cancer type, disease burden, prior treatment history, and individual biology. |
| One-time cellular infusion after preparation | Although evaluation, manufacturing, monitoring, and follow-up are extensive, the CAR-T cells are generally given as a single infusion rather than repeated cycles of infusion-based therapy. |
| Detailed specialist monitoring | Care is structured around early recognition and treatment of immune-related side effects, infections, low blood counts, and neurological symptoms. |
| Individualized post-treatment planning | Response assessment, infection prevention, immunoglobulin support when needed, rehabilitation, and long-term surveillance are tailored to your clinical needs. |
CAR-T Cell Therapy Recovery Timeline
Recovery varies considerably, but the following timeline outlines what many patients can expect during and after CAR-T cell therapy.
Longer TermLong-term surveillance focuses on cancer response, immune recovery, late infections, low immunoglobulin levels, vaccination planning, and any continuing effects on blood counts or organ function.
| Time Period | What Patients Can Expect |
|---|---|
| Day 1 | The CAR-T cells are infused through a vein. Vital signs and symptoms are monitored closely, and patients may remain under hospital observation depending on the treatment plan. |
| First Week | Fever, fatigue, low blood pressure, low oxygen levels, or other signs of cytokine release syndrome may occur. Blood counts can fall, and clinical teams monitor for infection and neurological changes. |
| Second to Third Week | Some patients continue to need inpatient care, while others may be followed very closely near the treatment center. Blood tests, neurological reviews, supportive medications, and transfusions may be required. |
| First Month | Energy levels may still be limited. Follow-up testing begins to assess early response and blood-count recovery. Patients are generally advised to avoid infection exposure and remain close to the treatment center. |
| Months 2 to 3 | Many patients gradually resume more daily activities, although fatigue and immune suppression may persist. Ongoing imaging, blood tests, marrow testing when appropriate, and infection prevention remain important. |
What Influences Outcomes and a Good Result?
CAR-T therapy outcomes are influenced by multiple clinical factors. The type of blood cancer, its genetic and molecular characteristics, the target antigen expressed on cancer cells, disease burden at the time of infusion, and the number and nature of previous treatments all matter. Patients with rapidly progressive disease may require particularly careful planning during the manufacturing period.
General health also plays an important role. Heart, lung, liver, kidney, and neurological function can affect treatment tolerance. Active infection, poor nutritional status, frailty, and severely reduced blood counts may increase risk, although these factors are assessed individually rather than through a single rule. A patient’s ability to remain near the treating center and have a reliable caregiver during the early recovery period is also clinically relevant.
Equally important is the experience and readiness of the care environment. CAR-T therapy requires a team familiar with cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention, transfusion support, and critical care escalation. Side effects can often be managed effectively when they are recognized early and treated according to established protocols.
Response is monitored using disease-specific methods. These may include positron emission tomography-computed tomography for lymphoma, bone marrow testing for leukemia, blood and urine studies for myeloma, and molecular assessments when clinically indicated. A response seen early after treatment is encouraging, but long-term follow-up remains essential because every patient’s disease course is different.
Why International Patients Choose Acibadem for CAR-T Cell Therapy
CAR-T therapy requires more than a single infusion appointment. It involves a carefully coordinated clinical pathway, from eligibility review and cellular collection to inpatient monitoring, supportive treatment, response assessment, and communication with the patient’s physicians at home. At Acibadem, CAR-T care is planned through multidisciplinary collaboration and internationally informed, evidence-based treatment protocols.
Patients are evaluated by experienced hematology and oncology specialists working alongside cellular therapy, transplant, pathology, radiology, intensive care, neurology, infectious disease, pharmacy, and nursing teams. Complex cases may be discussed in specialist boards to ensure that treatment recommendations reflect the full clinical picture rather than one aspect of the disease alone.
Acibadem’s JCI-accredited hospitals provide the clinical infrastructure needed for advanced cancer care, including modern diagnostic pathways, specialized laboratory support, blood-bank services, infection-control measures, intensive care resources, and technology for detailed monitoring before and after cellular therapy. The technologies used are selected to support accurate diagnosis, safe cell-handling processes, close monitoring, and personalized response assessment.
For international patients, medical coordination is paired with practical support. Acibadem International teams assist with appointment planning, medical-record review, interpreter services in more than 20 languages, travel-related coordination, and communication throughout the care journey. Before travel, patients can share pathology reports, imaging, treatment summaries, and laboratory results for preliminary review. This helps the treating team understand the urgency of the situation and advise on the next appropriate steps.
Personalized treatment planning remains central. Some patients may be suitable for CAR-T therapy immediately; others may first need disease control, infection treatment, additional diagnostic clarification, or an alternative therapy. The aim is not simply to deliver a complex treatment, but to determine whether it is the right treatment, at the right time, for the individual patient.
Taking the Next Step
CAR-T cell therapy can be an important option for selected people facing relapsed or refractory blood cancer, particularly when previous treatments have not provided adequate control. The decision should be made after a detailed review by a hematology and cellular therapy team that can assess diagnosis, treatment history, disease activity, overall health, and available alternatives.
If you are considering CAR-T therapy, a consultation or second opinion can help clarify eligibility, expected timelines, possible risks, supportive-care needs, and how treatment may fit into your broader cancer plan. Bringing complete pathology, imaging, laboratory results, and a summary of prior therapies allows the team to provide the most informed guidance.
This information is intended for general educational purposes and does not replace professional medical advice, diagnosis, or treatment. Decisions about CAR-T cell therapy should always be made with qualified healthcare professionals familiar with your individual medical condition.
Preparation
- Patients undergo detailed eligibility assessments, including blood tests, imaging, and evaluation by oncology and hematology teams. T cells are collected through leukapheresis and sent for laboratory modification before treatment. Lymphodepleting chemotherapy is typically given shortly before the CAR-T cell infusion.
Aftercare
- Close hospital monitoring is required after infusion because immune-related side effects, including cytokine release syndrome and neurological symptoms, can occur. Regular blood tests, infection prevention measures, and follow-up with the oncology team are essential. Patients should arrange for a caregiver and remain near the treatment center during the early recovery period.
Turkey vs UK, Germany & USA
CAR-T cell therapy is a highly personalised cancer treatment, so costs and care pathways vary considerably between countries and between patients. The final plan depends on cancer type, prior treatments, cell-manufacturing requirements, hospital monitoring needs and eligibility assessment.
International comparisons should consider more than the treatment itself, including access pathways, hospital experience, laboratory and manufacturing coordination, inpatient monitoring, travel support and what is included in a quoted package.
| Factor | Turkey | UK | Germany | USA |
|---|---|---|---|---|
| Access pathway | Private international-patient pathways may enable coordinated assessment and treatment planning. | Public and private pathways may differ; referral and eligibility processes can affect timing. | University and specialist centres commonly provide access through referral-based pathways. | Access may depend on specialist-centre referral, insurance authorisation and network coverage. |
| Hospital and specialist team | Costs may reflect the treating centre, haematology team, intensive monitoring capability and international-care services. | Costs and access can vary between public services and private cancer centres. | Costs may vary by hospital type, specialist expertise and care setting. | Costs may vary substantially by hospital system, physician network and insurance arrangements. |
| Accreditation and quality systems | Selected hospitals, including JCI-accredited facilities, may offer internationally recognised quality and safety frameworks. | Hospitals are regulated through national healthcare quality systems. | Hospitals operate under German regulatory and quality requirements; specialist-centre experience is relevant. | Hospitals follow national and state regulations; centre accreditation and programme experience may differ. |
| Waiting and coordination | International teams may coordinate records review, appointments, travel and treatment scheduling. | Timing can depend on clinical urgency, referral processes and capacity. | Timing can depend on referral, diagnostic review, manufacturing coordination and centre capacity. | Timing can depend on insurance approval, referral, manufacturing coordination and centre capacity. |
| Travel and language support | International patient services may assist with interpreters, transfers, accommodation guidance and medical documentation. | English is the main care language; overseas patients arrange travel and local support independently or through providers. | English-speaking support may be available at international departments, depending on the hospital. | English is the main care language; international travel, accommodation and insurance arrangements can add complexity. |
| What a package may include | May include evaluation, cell collection coordination, treatment admission, physician care, routine monitoring and international-patient support; inclusions vary. | Private quotes may cover selected clinical services, while public eligibility pathways follow separate funding rules. | Quotes may include hospital and physician services, diagnostics and monitoring, subject to treatment plan and exclusions. | Charges may be separated across hospital, physicians, laboratory services, pharmacy, insurance and follow-up care. |
What affects your final cost
- The specific blood cancer, disease status and whether CAR-T therapy is clinically appropriate.
- The CAR-T product selected and cell-manufacturing requirements.
- Pre-treatment testing, imaging, pathology review and specialist consultations.
- Need for bridging treatment, lymphodepleting treatment or management of active infection.
- Length and level of hospital monitoring, including intensive-care support if complications occur.
- Medication, transfusions, follow-up testing, travel, accommodation and interpreter needs.
Compare your options
CAR-T cell therapy is one option within the treatment of certain blood cancers. The most appropriate approach is decided by a haematology or oncology specialist after review of diagnosis, prior therapy, overall health, disease activity and treatment goals.
| Option | What it is | Typical use | Key considerations |
|---|---|---|---|
| CAR-T cell therapy | A personalised immunotherapy using a patient's modified T cells to recognise cancer cells. | Used for selected blood cancers when standard treatments have not worked, have stopped working or are unsuitable. | Requires eligibility assessment, cell collection, manufacturing coordination and close monitoring for immune-related side effects. |
| Bispecific antibody therapy | An immunotherapy that brings immune cells into contact with cancer cells. | May be used for selected relapsed or refractory blood cancers. | Can also cause immune-related reactions and requires specialist monitoring; availability depends on diagnosis and local approval. |
| Stem cell transplant | A procedure using blood-forming stem cells after intensive treatment. | May be considered for certain blood cancers in appropriate patients. | Suitability depends on disease features, donor availability where relevant, prior therapy and overall fitness. |
| Targeted therapy | Medicines designed to act on specific cancer-related pathways or markers. | Used when the cancer has a targetable feature or when a targeted medicine is appropriate for the disease type. | Testing may be needed to identify suitable targets; side effects and treatment duration vary. |
| Chemotherapy or immunochemotherapy | Drug treatment that attacks cancer cells, sometimes combined with antibody-based medicines. | May be used as initial treatment, later-line therapy or temporary disease control before another treatment. | Choice depends on previous treatment response, cancer characteristics and the patient's health status. |
| Clinical trial | Research-based access to emerging therapies or new treatment combinations. | May be considered when standard options are limited or when a suitable study is available. | Eligibility criteria, location, potential benefits and uncertainties should be reviewed carefully with a specialist. |
Trusted care for international patients
General information only — not medical or financial advice. Final costs depend on the factors above and your individual case; request a free, personalised quote.
Diseases This Treats
Frequently Asked Questions
What is CAR-T cell therapy and how does it work?
CAR-T cell therapy is an advanced immunotherapy that uses a patient’s own T cells to recognize and attack certain cancer cells. Blood is collected, and the T cells are modified in a specialized laboratory to carry a chimeric antigen receptor, or CAR. After preparation, the cells are infused back into the patient. The modified cells can identify a target on cancer cells and activate an immune response against them.
Which cancers can be treated with CAR-T cell therapy?
CAR-T cell therapy is mainly used for selected blood cancers, particularly some types of B-cell lymphoma, acute lymphoblastic leukemia, multiple myeloma, and other hematologic malignancies. Its use depends on the exact diagnosis, cancer subtype, prior treatments, disease activity, and availability of an appropriate CAR-T product. It is not currently a standard treatment for most solid tumors. Acibadem specialists can review pathology and treatment history to determine whether CAR-T therapy may be suitable.
Who is eligible for CAR-T cell therapy?
Eligibility is determined individually by a multidisciplinary cancer team. Doctors consider the type and stage of cancer, previous treatments, response or relapse history, overall fitness, organ function, infection status, and ability to remain under close monitoring. CAR-T therapy is often considered when certain blood cancers have returned or have not responded adequately to standard treatment. A personalized assessment is essential because eligibility criteria may differ between CAR-T products and clinical circumstances.
What happens during the CAR-T cell therapy process?
The process usually begins with detailed testing and consultation. T cells are collected from the blood through a procedure called leukapheresis. The cells are then prepared in a laboratory, which may take several weeks. During this period, some patients need temporary treatment to control the cancer. Before infusion, lymphodepleting chemotherapy is commonly given. The CAR-T cells are infused intravenously, followed by intensive monitoring for early treatment-related reactions.
How long do international patients need to stay in Turkey for CAR-T therapy?
The required stay depends on the treatment plan, cell-manufacturing timeline, medical condition, and recovery after infusion. Patients generally need to remain near the treating center for close observation during the early period after CAR-T cell infusion, when side effects are most likely to occur. International patients should plan for a potentially extended stay and should not arrange return travel until their clinical team considers it appropriate. Acibadem’s international patient services can help coordinate appointments and follow-up planning.
What are the main side effects of CAR-T cell therapy?
CAR-T cell therapy can cause significant side effects, so it must be delivered by experienced teams with appropriate monitoring. The most recognized reactions are cytokine release syndrome, which may cause fever, low blood pressure, breathing difficulties, and fatigue, and neurologic effects such as confusion, headache, tremor, or speech changes. Low blood counts, infections, and fatigue may also occur. Many reactions can be managed effectively when identified early, which is why close hospital observation is important.
Will I need to stay in hospital after CAR-T cell infusion?
Many patients are admitted to hospital or monitored very closely after CAR-T cell infusion, especially during the first days and weeks. The exact approach depends on the CAR-T product, cancer type, medical condition, and local clinical protocols. Doctors monitor temperature, blood pressure, oxygen levels, neurologic symptoms, blood counts, and signs of infection. Even after discharge, patients usually need frequent outpatient visits and should stay close to the treatment center for a period recommended by their care team.
Can CAR-T cell therapy be used after chemotherapy, stem cell transplant, or other treatments have failed?
Yes, CAR-T therapy may be considered for some patients whose blood cancer has relapsed after previous treatment or has not responded sufficiently to chemotherapy, immunotherapy, targeted therapy, or stem cell transplantation. However, it is not appropriate for every patient in this situation. Specialists review prior treatment records, pathology results, imaging, bone marrow findings, current disease burden, and overall health. Acibadem’s hematology and oncology teams can provide a personalized assessment of possible next-step options.
How should I prepare for CAR-T cell therapy as an international patient?
Before traveling, patients should share complete medical records, including pathology reports, imaging scans, laboratory results, discharge summaries, medication lists, and details of prior cancer treatments. The treating team may request additional tests or pathology review before confirming a plan. It is helpful to travel with a caregiver, as patients may need support during monitoring and recovery. Discuss vaccinations, infection precautions, travel timing, accommodation, interpreter needs, and emergency contact arrangements with the international patient team.
How much does CAR-T cell therapy cost in Turkey?
The cost of CAR-T cell therapy varies considerably because it includes evaluation, cell collection and processing, hospital care, chemotherapy before infusion, medications, laboratory testing, imaging, management of side effects, and follow-up. Costs may also differ according to the CAR-T product, diagnosis, treatment complexity, and length of hospitalization. After reviewing your medical information and proposed care plan, Acibadem’s international patient team can provide a clearer individualized estimate and explain what services are included.
What has the greatest effect on the cost of CAR-T cell therapy?
Key cost drivers include the CAR-T product and manufacturing process, pre-treatment assessment, hospital admission, monitoring needs, medications, treatment of complications and follow-up care. Travel and accommodation may also affect the overall budget for international patients.
What is usually included in a CAR-T treatment quote?
Inclusions vary by hospital and country. A quote may include consultations, diagnostic review, cell collection coordination, hospital care, physician services, routine monitoring and selected medications. Ask for a written breakdown of inclusions, exclusions and possible additional charges.
Can I receive a quote before travelling to Turkey?
A preliminary personalised quote may be prepared after the specialist team reviews relevant medical records, such as pathology reports, imaging, treatment history and recent blood tests. A final plan may change after clinical assessment. A free consultation can help clarify the likely pathway.
Why might the final cost change after the initial assessment?
The treatment plan can change if additional testing is needed, the cancer requires bridging treatment, admission is extended, complications occur or another therapy is considered more suitable. CAR-T treatment is individualised, so estimates should be understood as conditional on the clinical plan.
Does JCI accreditation matter when choosing a hospital for CAR-T therapy?
JCI accreditation is one indicator of established quality and patient-safety standards. It should be considered alongside the centre's haematology expertise, CAR-T programme capabilities, emergency and intensive-care support, multidisciplinary review process and services for international patients.